Review
doi: 10.1089/10430349950016807.
High-capacity adenoviral vectors for gene transfer and somatic gene therapy
Affiliations
- PMID: 10543611
- DOI: 10.1089/10430349950016807
Item in Clipboard
Review
High-capacity adenoviral vectors for gene transfer and somatic gene therapy
Hum Gene Ther.
.
Abstract
The availability of efficient and nontoxic gene delivery technologies is fundamental to the translation of therapeutic concepts into clinical practice by gene transfer. High-capacity adenoviral (HC-Ad) vectors are characterized by the ability to transduce cells in vitro and in vivo with more than 30 kb of nonviral DNA. This quality allows simultaneous gene transfer of several expression cassettes, large promoters, and some genes in their natural genomic context. Because all viral coding sequences are removed from these vectors, safety is considerably improved compared with previous-generation adenoviral vectors.
Similar articles
-
[Gene therapy: new developments].Praxis (Bern 1994). 2002 Dec 18;91(51-52):2227-35. doi: 10.1024/0369-8394.91.51.2227. Praxis (Bern 1994). 2002. PMID: 12564039 Review. German.
-
Quantification of high-capacity helper-dependent adenoviral vector genomes in vitro and in vivo, using quantitative TaqMan real-time polymerase chain reaction.Hum Gene Ther. 2006 May;17(5):531-44. doi: 10.1089/hum.2006.17.531. Hum Gene Ther. 2006. PMID: 16716110 Free PMC article.
-
High-capacity 'gutless' adenoviral vectors.Curr Opin Mol Ther. 2001 Oct;3(5):454-63. Curr Opin Mol Ther. 2001. PMID: 11699889 Review.
-
Improvements in gene therapy: averting the immune response to adenoviral vectors.BioDrugs. 2002;16(1):3-10. doi: 10.2165/00063030-200216010-00001. BioDrugs. 2002. PMID: 11908997 Review.
-
Improved high-capacity adenoviral vectors for high-level neuron-restricted gene transfer to the CNS.J Virol Methods. 2006 Sep;136(1-2):30-7. doi: 10.1016/j.jviromet.2006.03.031. Epub 2006 May 2. J Virol Methods. 2006. PMID: 16672163
Cited by
-
Gene therapy for type 1 diabetes: is it ready for the clinic?Immunol Res. 2006;36(1-3):83-9. doi: 10.1385/IR:36:1:83. Immunol Res. 2006. PMID: 17337769 Review.
-
Let There Be Light: Gene and Cell Therapy for Blindness.Hum Gene Ther. 2016 Feb;27(2):134-47. doi: 10.1089/hum.2015.147. Hum Gene Ther. 2016. PMID: 26751519 Free PMC article. Review.
-
Antibody-mediated targeting of an adenovirus vector modified to contain a synthetic immunoglobulin g-binding domain in the capsid.J Virol. 2003 Feb;77(3):2093-104. doi: 10.1128/jvi.77.3.2093-2104.2003. J Virol. 2003. PMID: 12525644 Free PMC article.
-
Peripheral infection with adenovirus causes unexpected long-term brain inflammation in animals injected intracranially with first-generation, but not with high-capacity, adenovirus vectors: toward realistic long-term neurological gene therapy for chronic diseases.Proc Natl Acad Sci U S A. 2000 Jun 20;97(13):7482-7. doi: 10.1073/pnas.120474397. Proc Natl Acad Sci U S A. 2000. PMID: 10840055 Free PMC article.
-
Gene Therapy in the Anterior Eye Segment.Curr Gene Ther. 2022;22(2):104-131. doi: 10.2174/1566523221666210423084233. Curr Gene Ther. 2022. PMID: 33902406 Free PMC article. Review.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
